Serena Zhao Yang-Loudin, MD
Urology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: John Muir Medical Center - Walnut Creek Campus · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Yang-Loudin’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A156420 · Current
Licensed to practise in California · since 2018 · expires 2028-04-30 · Baylor College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- John Muir Medical Center - Walnut Creek CampusWalnut Creek, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of John Muir Health, which runs 3 hospitalsPatients rate it 3 of 5 · 77% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Abdominopelvic accidental puncture or laceration rate: 2.01 (1.17 to 2.85) · 2,206 cases, Jul 2022 – Jun 2024Worse than the national rate — Death rate among surgical inpatients with serious treatable complications: 222.42 (177.82 to 267.02) · 120 cases, Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.4 (0.91 to 1.9) · 9,764 cases, Jul 2022 – Jun 2024Worse than the national rate — SSI - Colon Surgery: 2.734, Oct 2024 – Sep 2025Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.536, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.341, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.455, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.245, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for John Muir Medical Center - Walnut Creek Campus
Behind the star rating — Deaths: 3 better, 2 the same, 2 worse of 7 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 3 better, 5 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 2.01 (1.17 to 2.85) · 2,206 cases | Worse | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 222.42 (177.82 to 267.02) · 120 cases | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.4 (0.91 to 1.9) · 9,764 cases | Worse | Jul 2022 – Jun 2024 |
| SSI - Colon SurgeryInfections | 2.734 | Worse | Oct 2024 – Sep 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.536 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.341 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.455 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.245 | Better | Oct 2024 – Sep 2025 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.14 (0.87 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 131 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 148 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 695 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.5 · 827 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 14.1 · 509 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 4,483 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.35 (0.18 to 0.53) · 11,630 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.05 to 0.39) · 11,793 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.33 (1.69 to 4.96) · 3,268 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.37 (0 to 2.94) · 1,631 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.76 (1.43 to 4.09) · 3,066 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.12 (0.22 to 12.02) · 1,580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.43 (1.21 to 7.64) · 1,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.82 (0.4 to 3.24) · 685 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 615 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 1.88 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 93 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 729 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.1 · 91 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13 · 736 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 34.8 · 842 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.7 · 818 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.3 (3.3 to 8.4) · 28 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.2 to 15.5) · 28 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 584 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.4 · 139 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.9) · 222 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 321 cases | No different | Jan 2024 – Dec 2024 |
What patients said (758 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 77% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$215,820
Medicare paid this office $215,820 for 361 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 191 | $39,267 | $116 |
| Short return visit (20+ min) | 196 | $31,396 | $86 |
| Diagnostic exam of bladder and urethra using an endoscope | 79 | $22,350 | $240 |
| New patient visit (45+ min) | 133 | $19,115 | $144 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 17 | $6,500 | $382 |
See all 16 services
| Return visit (30+ min) | 191 | $39,267 | $116 |
| Short return visit (20+ min) | 196 | $31,396 | $86 |
| Diagnostic exam of bladder and urethra using an endoscope | 79 | $22,350 | $240 |
| New patient visit (45+ min) | 133 | $19,115 | $144 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 17 | $6,500 | $382 |
| Insertion of device into abdomen with pressure and urine flow rate study | 16 | $3,329 | $208 |
| Ultrasound measurement of bladder capacity after voiding | 171 | $2,796 | $12 |
| Ultrasound scan of pelvic region through rectum | 19 | $2,788 | $147 |
| New patient visit (30+ min) | 26 | $2,498 | $96 |
| Long return visit (40+ min) | 11 | $2,060 | $158 |
| Simple bladder irrigation and/or instillation | 21 | $1,799 | $58 |
| Urinalysis, manual test | 178 | $788 | $3 |
| Electronic assessment of bladder emptying | 50 | $740 | $12 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 37 | $614 | $15 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 17 | $554 | $33 |
| Imaging guidance for procedure, 60 minutes or less | 15 | $281 | $13 |
Procedures Medicare counted
| Prostate resection | 1-10 | None |
Who their Medicare patients are
361 Original Medicare patients in 2024. Average age 76 · Under 65 5% · 85 and older 16% · Women 55% · Also on Medicaid 22% · Health risk score 1.21. At or below the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 69% · Depression 25% · Diabetes 24% · Chronic kidney disease 23% · Cancer 22% · Atrial fibrillation 20% · Coronary heart disease 19% · Heart failure 13% · COPD 13% · Stroke 9% · Dementia 8%.
The office billed $938,323, Medicare allowed $283,204 and paid $215,820; for 8,305 services of 79 kinds; $24,953 of it was for drugs given in the office and $190,867 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 361 | 8,305 | 76 | 1.21 | $938,323 | $215,820 |
| 2023 | 362 | 5,951 | 76 | 1.20 | $1,021,418 | $224,520 |
| 2022 | 243 | 6,823 | 75 | 1.36 | $625,353 | $145,980 |
| 2021 | 261 | 1,749 | 74 | 1.56 | $561,607 | $96,515 |
| 2020 | 247 | 1,833 | 73 | 1.95 | $625,523 | $76,670 |
| 2019 | 369 | 2,444 | 72 | 1.67 | $927,166 | $118,586 |
| 2018 | 99 | 246 | 73 | 1.53 | $98,133 | $16,743 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 15 services
| Return visit (30+ min) | 177 | $35,256 | $116 |
| Diagnostic exam of bladder and urethra using an endoscope | 93 | $26,663 | $242 |
| New patient visit (45+ min) | 198 | $26,077 | $132 |
| Short return visit (20+ min) | 164 | $21,531 | $81 |
| Insertion of sacral nerve neurostimulator electrode array | 11 | $11,906 | $1,082 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 17 | $6,690 | $372 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 15 | $5,537 | $326 |
| Ultrasound scan of pelvic region through rectum | 23 | $3,526 | $147 |
| New patient visit (30+ min) | 32 | $3,008 | $94 |
| Long return visit (40+ min) | 14 | $2,738 | $144 |
| Ultrasound measurement of bladder capacity after voiding | 146 | $2,028 | $11 |
| Urinalysis, manual test | 193 | $853 | $3 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 17 | $571 | $32 |
| Imaging guidance for procedure, 60 minutes or less | 23 | $345 | $14 |
| Electronic assessment of bladder emptying | 25 | $286 | $10 |
2022: 11 services
| New patient visit (45+ min) | 173 | $24,755 | $143 |
| Diagnostic exam of bladder and urethra using an endoscope | 66 | $18,026 | $250 |
| Return visit (30+ min) | 87 | $15,603 | $117 |
| Short return visit (20+ min) | 100 | $13,868 | $86 |
| Ultrasound scan of pelvic region through rectum | 21 | $3,089 | $147 |
| Long return visit (40+ min) | 15 | $3,061 | $170 |
| New patient visit (30+ min) | 17 | $1,795 | $106 |
| Ultrasound measurement of bladder capacity after voiding | 116 | $1,607 | $11 |
| Simple bladder irrigation and/or instillation | 15 | $1,287 | $76 |
| Urinalysis, manual test | 131 | $597 | $3 |
| Electronic assessment of bladder emptying | 11 | $119 | $8 |
2021: 11 services
| Diagnostic exam of bladder and urethra using an endoscope | 68 | $17,284 | $203 |
| Return visit (30+ min) | 93 | $12,634 | $106 |
| Short return visit (20+ min) | 123 | $11,291 | $73 |
| New patient visit (45+ min) | 44 | $5,974 | $136 |
| Long return visit (40+ min) | 20 | $3,606 | $150 |
| Biopsy of prostate gland | 14 | $2,878 | $206 |
| Ultrasound scan of pelvic region through rectum | 13 | $1,602 | $123 |
| Simple bladder irrigation and/or instillation | 18 | $1,376 | $69 |
| Automated urinalysis test | 128 | $419 | $2 |
| Ultrasound measurement of bladder capacity after voiding | 31 | $279 | $9 |
| Injection, garamycin, gentamicin, up to 80 mg | 11 | $16 | None |
2020: 11 services
| Diagnostic exam of bladder and urethra using an endoscope | 53 | $10,985 | $174 |
| Short return visit (20+ min) | 118 | $8,279 | $55 |
| New patient visit (45+ min) | 54 | $6,436 | $119 |
| Return visit (30+ min) | 53 | $5,979 | $82 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 11 | $2,748 | $250 |
| New patient visit (30+ min) | 18 | $1,405 | $78 |
| Simple bladder irrigation and/or instillation | 15 | $1,359 | $65 |
| Simple insertion of temporary bladder tube | 14 | $1,219 | $49 |
| Telephone medical discussion with physician, 11-20 minutes | 18 | $1,146 | $57 |
| Automated urinalysis test | 103 | $357 | $2 |
| Ultrasound measurement of bladder capacity after voiding | 35 | $306 | $8 |
2019: 13 services
| Diagnostic exam of bladder and urethra using an endoscope | 98 | $16,429 | $156 |
| New patient visit (45+ min) | 132 | $15,962 | $121 |
| Short return visit (20+ min) | 152 | $13,156 | $59 |
| Return visit (30+ min) | 78 | $7,343 | $84 |
| New patient visit (30+ min) | 45 | $3,915 | $87 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 11 | $2,497 | $227 |
| Simple bladder irrigation and/or instillation | 23 | $1,775 | $63 |
| Simple insertion of temporary bladder tube | 21 | $1,553 | $50 |
| Ultrasound measurement of bladder capacity after voiding | 129 | $1,451 | $9 |
| Insertion of lower leg neurostimulator electrode | 11 | $1,224 | $102 |
| Instillation of anti-cancer drug into bladder | 11 | $1,209 | $71 |
| Automated urinalysis test | 221 | $842 | $2 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $173 | $16 |
2018: 7 services
| New patient visit (45+ min) | 26 | $3,512 | $135 |
| New patient visit (30+ min) | 34 | $3,020 | $89 |
| Diagnostic exam of bladder and urethra using an endoscope | 14 | $1,958 | $140 |
| Return visit (30+ min) | 14 | $1,248 | $89 |
| Short return visit (20+ min) | 13 | $786 | $60 |
| Automated urinalysis test | 65 | $201 | $3 |
| Ultrasound measurement of bladder capacity after voiding | 11 | $150 | $14 |
Drugs they prescribed that Part D paid
$312,609
Pharmacies billed $312,609 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (24 of 1,618) in 2024. At or below the middle of the specialty; the typical urology clinician is at 2%.
1,199 generic and fewer than 11 brand-name prescriptions · $312,609 in drug cost · 269 antibiotic prescriptions to 143 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Gemtesa | 219 | $173,371 | $792 |
| Myrbetriq | 154 | $94,623 | $614 |
| Methenamine Hippurate | 123 | $10,490 | $85 |
| Estradiol | 98 | $6,771 | $69 |
| Tamsulosin | 314 | $4,148 | $13 |
See all 20 drugs
| Gemtesa | 219 | $173,371 | $792 |
| Myrbetriq | 154 | $94,623 | $614 |
| Methenamine Hippurate | 123 | $10,490 | $85 |
| Estradiol | 98 | $6,771 | $69 |
| Tamsulosin | 314 | $4,148 | $13 |
| Nitrofurantoin Mono-Macro | 96 | $2,960 | $31 |
| Finasteride | 229 | $2,783 | $12 |
| Potassium Citrate Er | 18 | $2,481 | $138 |
| Testosterone | 13 | $1,381 | $106 |
| Dutasteride | 11 | $1,059 | $96 |
| Cefdinir | 52 | $675 | $13 |
| Clotrimazole-Betamethasone | 17 | $227 | $13 |
| Amoxicillin-Clavulanate Potass | 35 | $185 | $5 |
| Alfuzosin Hcl Er | 11 | $185 | $17 |
| Cephalexin | 13 | $179 | $14 |
| Sulfamethoxazole-Trimethoprim | 33 | $127 | $4 |
| Hydrocodone-Acetaminophen | 15 | $105 | $7 |
| Testosterone Cypionate | 11 | $86 | $8 |
| Ciprofloxacin | 19 | $46 | $2 |
| Levofloxacin | 11 | $21 | $2 |
Year by year
| 2024 | 1,618 | 388 | 2% (24) | None | $312,609 |
| 2023 | 1,352 | 326 | 3% (45) | None | $233,853 |
| 2022 | 851 | 275 | 4% (32) | 18% | $81,409 |
| 2021 | 756 | 223 | 4% (33) | None | $56,904 |
| 2020 | 695 | 191 | 5% (33) | None | $71,136 |
| 2019 | 661 | 238 | 8% (50) | None | $40,019 |
| 2018 | 107 | 61 | 10% (11) | None | $7,073 |
| 2017 | 129 | 64 | 28% (36) | None | $3,701 |
| 2016 | 150 | 61 | None | None | $4,548 |
| 2015 | 109 | 55 | 23% (25) | 16% | $2,648 |
| 2014 | 115 | 43 | 30% (34) | None | $4,859 |
| 2013 | 89 | 32 | 23% (20) | None | $2,622 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 18 drugs
| Myrbetriq | 203 | $120,174 | $592 |
| Gemtesa | 96 | $67,934 | $708 |
| Methenamine Hippurate | 127 | $13,020 | $103 |
| Estradiol | 58 | $6,572 | $113 |
| Tamsulosin | 262 | $6,013 | $23 |
| Finasteride | 146 | $3,695 | $25 |
| Potassium Citrate Er | 14 | $3,233 | $231 |
| Nitrofurantoin Mono-Macro | 44 | $1,631 | $37 |
| Cefdinir | 70 | $1,393 | $20 |
| Alfuzosin Hcl Er | 13 | $715 | $55 |
| Sulfamethoxazole-Trimethoprim | 42 | $236 | $6 |
| Hydrocodone-Acetaminophen | 26 | $196 | $8 |
| Ciprofloxacin | 32 | $132 | $4 |
| Cephalexin | 18 | $121 | $7 |
| Amoxicillin-Clavulanate Potass | 22 | $111 | $5 |
| Levofloxacin | 21 | $107 | $5 |
| Oxybutynin Chloride Er | 12 | $79 | $7 |
| Amitriptyline | 12 | $53 | $4 |
2022: 17 drugs
| Myrbetriq | 61 | $37,004 | $607 |
| Gemtesa | 21 | $10,248 | $488 |
| Premarin | 14 | $6,063 | $433 |
| Estradiol | 41 | $4,657 | $114 |
| Tamsulosin | 197 | $4,170 | $21 |
| Methenamine Hippurate | 27 | $3,080 | $114 |
| Finasteride | 130 | $2,736 | $21 |
| Potassium Citrate Er | 14 | $2,161 | $154 |
| Oxybutynin Chloride Er | 23 | $1,199 | $52 |
| Nitrofurantoin Mono-Macro | 41 | $794 | $19 |
| Cefdinir | 24 | $353 | $15 |
| Sulfamethoxazole-Trimethoprim | 36 | $162 | $4 |
| Hydrocodone-Acetaminophen | 17 | $132 | $8 |
| Amoxicillin-Clavulanate Potass | 18 | $113 | $6 |
| Cephalexin | 13 | $111 | $9 |
| Ciprofloxacin | 33 | $91 | $3 |
| Water | 14 | $79 | $6 |
2021: 14 drugs
| Myrbetriq | 45 | $27,576 | $613 |
| Tamsulosin | 220 | $4,020 | $18 |
| Finasteride | 158 | $3,800 | $24 |
| Oxybutynin Chloride Er | 43 | $2,339 | $54 |
| Estradiol | 11 | $1,785 | $162 |
| Nitrofurantoin Mono-Macro | 11 | $498 | $45 |
| Doxazosin Mesylate | 12 | $428 | $36 |
| Nitrofurantoin | 13 | $424 | $33 |
| Oxybutynin Chloride | 22 | $291 | $13 |
| Cefdinir | 11 | $133 | $12 |
| Ciprofloxacin | 36 | $104 | $3 |
| Amoxicillin-Clavulanate Potass | 12 | $69 | $6 |
| Sulfamethoxazole-Trimethoprim | 14 | $69 | $5 |
| Tramadol | 21 | $57 | $3 |
2020: 14 drugs
| Myrbetriq | 82 | $44,566 | $543 |
| Tamsulosin | 167 | $2,980 | $18 |
| Trospium Chloride | 32 | $2,823 | $88 |
| Finasteride | 120 | $2,805 | $23 |
| Nitrofurantoin | 14 | $795 | $57 |
| Oxybutynin Chloride Er | 16 | $770 | $48 |
| Cefdinir | 14 | $242 | $17 |
| Oxybutynin Chloride | 20 | $209 | $10 |
| Lidocaine | 15 | $203 | $14 |
| Amoxicillin-Clavulanate Potass | 19 | $141 | $7 |
| Ciprofloxacin | 45 | $109 | $2 |
| Sulfamethoxazole-Trimethoprim | 19 | $104 | $5 |
| Hydrocodone-Acetaminophen | 13 | $68 | $5 |
| Tramadol | 16 | $32 | $2 |
2019: 11 drugs
| Myrbetriq | 21 | $13,095 | $624 |
| Toviaz | 12 | $4,728 | $394 |
| Oxybutynin Chloride Er | 83 | $3,824 | $46 |
| Tamsulosin | 143 | $3,298 | $23 |
| Trospium Chloride | 23 | $2,789 | $121 |
| Finasteride | 96 | $2,361 | $25 |
| Oxybutynin Chloride | 21 | $341 | $16 |
| Ciprofloxacin | 74 | $340 | $5 |
| Cefdinir | 19 | $272 | $14 |
| Hydrocodone-Acetaminophen | 37 | $192 | $5 |
| Sulfamethoxazole-Trimethoprim | 18 | $75 | $4 |
2018: 3 drugs
| Oxybutynin Chloride Er | 14 | $541 | $39 |
| Tamsulosin | 12 | $219 | $18 |
| Ciprofloxacin | 17 | $116 | $7 |
2017: 4 drugs
| Tamsulosin | 18 | $199 | $11 |
| Oxybutynin Chloride | 12 | $173 | $14 |
| Oxycodone | 19 | $172 | $9 |
| Hydrocodone-Acetaminophen | 15 | $73 | $5 |
2016: 4 drugs
| Trospium Chloride | 28 | $639 | $23 |
| Warfarin | 21 | $318 | $15 |
| Ciprofloxacin | 15 | $147 | $10 |
| Sulfamethoxazole-Trimethoprim | 13 | $118 | $9 |
2015: 4 drugs
| Tamsulosin | 11 | $162 | $15 |
| Oxycodone | 13 | $145 | $11 |
| Ciprofloxacin | 17 | $138 | $8 |
| Hydrocodone-Acetaminophen | 11 | $63 | $6 |
2014: 2 drugs
| Oxycodone | 28 | $422 | $15 |
| Ciprofloxacin | 11 | $54 | $5 |
2013: 3 drugs
| Polyethylene Glycol 3350 | 12 | $170 | $14 |
| Oxycodone | 14 | $160 | $11 |
| Oxybutynin Chloride | 11 | $93 | $8 |
Money from drug and device companies
$809 in 2025
| 2025 | 14 | 23 | None | $809 |
| 2024 | 20 | 62 | None | $1,781 |
| 2023 | 21 | 50 | None | $1,500 |
| 2022 | 13 | 21 | None | $749 |
| 2021 | 2 | 2 | None | $37 |
| 2019 | 2 | 6 | None | $947 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | Spaceoar Vue System - 10ml | $162 | 2 payments
|
| Valencia Technologies | Ecoin Device Kit | $147 | 2 payments
|
| Bluewind Medical | Revi | $116 | 3 payments
|
| Verity Pharmaceuticals | Trelstar | $62 | 3 payments
|
| Janssen Biotech | Erleada | $59 | 2 payments
|
| Sumitomo Pharma America | Gemtesa | $43 | 2 payments
|
See all 23 published payments
| Urogen Pharma | Meals · 2025-12-01 | Zusduri | $34 |
| Dendreon Pharmaceuticals | Meals · 2025-11-12 | Provenge | $16 |
| Valencia Technologies | Meals · 2025-11-05 | Ecoin Device Kit | $29 |
| Sumitomo Pharma America | Meals · 2025-09-26 | Gemtesa | $29 |
| Valencia Technologies | Meals · 2025-09-05 | Ecoin Device Kit | $118 |
| Boston Scientific | Meals · 2025-08-19 | Spaceoar Vue System - 10ml | $56 |
| Boston Scientific | Meals · 2025-07-07 | Spaceoar Vue System - 10ml | $106 |
| Profound Medical | Meals · 2025-06-03 | Tulsa-Pro | $21 |
| Verity Pharmaceuticals | Meals · 2025-05-22 | Tlando | $16 |
| Sumitomo Pharma America | Meals · 2025-04-25 | Gemtesa | $14 |
| Progenics Pharmaceuticals | Meals · 2025-04-24 | Pylarify | $26 |
| Janssen Biotech | Meals · 2025-04-10 | Erleada | $36 |
| Bluewind Medical | Meals · 2025-04-02 | Revi | $27 |
| Pfizer | Meals · 2025-03-17 | Xtandi | $20 |
| Agiliti Surgical | Meals · 2025-02-21 | Sonablate Hifu | $14 |
| Verity Pharmaceuticals | Meals · 2025-02-13 | Trelstar | $20 |
| Ferring Pharmaceuticals | Meals · 2025-02-11 | Adstiladrin | $37 |
| Merck Sharp & Dohme | Meals · 2025-02-05 | Keytruda | $30 |
| Janssen Biotech | Meals · 2025-01-28 | Erleada | $22 |
| Verity Pharmaceuticals | Meals · 2025-01-15 | Trelstar | $26 |
| Pfizer | Meals · 2025-01-06 | Xtandi | $22 |
| Bluewind Medical | Travel · 2025-01-01 | Revi | $52 |
| Bluewind Medical | Meals · 2025-01-01 | Revi | $38 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $1,781
| Sumitomo Pharma America | Gemtesa | $427 | 16 payments
|
| Axonics | Bulkamid | $248 | 3 payments
|
| Bluewind Medical | Revi | $188 | 4 payments
|
| Urogen Pharma | Jelmyto | $168 | 10 payments
|
| Abbvie | Lupron Depot | $153 | 8 payments
|
| Coloplast | Titan | $75 | 1 payment
|
| Intuitive Surgical | Da Vinci Surgical System | $72 | 1 payment
|
| Pfizer | Xtandi | $54 | 3 payments
|
| Astellas Pharma US | Myrbetriq | $53 | 2 payments
|
| Janssen Biotech | Erleada | $53 | 2 payments
|
| Myriad Genetic Laboratories | Prolaris | $45 | 2 payments
|
| Boston Scientific | Spaceoar System | $38 | 2 payments
|
| Immunitybio | Anktiva | $35 | 1 payment
|
| Verity Pharmaceuticals | Trelstar | $30 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $27 | 1 payment
|
| PROCEPT BioRobotics | Aquabeam System | $27 | 1 payment
|
| Olympus America | Itind System | $24 | 1 payment
|
| CIVCO Medical Instruments | None | $23 | 1 payment
|
| MIMEDX Group | None | $22 | 1 payment
|
| Endo USA | Xiaflex | $19 | 1 payment
|
2023: $1,500
| Sumitomo Pharma America | Gemtesa | $193 | 7 payments
|
| Astellas Pharma US | Myrbetriq | $157 | 6 payments
|
| Axonics | Axonics | $147 | 3 payments
|
| UroGen Pharma | Jelmyto | $111 | 4 payments
|
| Boston Scientific | Lithovue | $105 | 2 payments
|
| Edap Technomed | None | $100 | 1 payment
|
| AbbVie | Botox | $86 | 4 payments
|
| Janssen Biotech | Erleada | $83 | 3 payments
|
| Koelis | Trinity | $82 | 1 payment
|
| Agiliti Surgical | Sonablate | $77 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $53 | 2 payments
|
| Accord Healthcare | Camcevi | $52 | 3 payments
|
| Pfizer | Xtandi | $46 | 3 payments
|
| Endo Pharmaceuticals | Aveed | $41 | 2 payments
|
| Coloplast | Titan | $38 | 2 payments
|
| PROCEPT BioRobotics | Aquabeam Robotic System | $25 | 1 payment
|
| Tolmar | Jatenzo | $23 | 1 payment
|
| Heron Therapeutics | Aponvie | $21 | 1 payment
|
| Smith+Nephew | Stravix | $21 | 1 payment
|
| Myriad Genetic Laboratories | Myrisk | $20 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $19 | 1 payment
|
2022: $749
| Dornier MedTech America | Dornier Medtech | $172 | 1 payment
|
| Astellas Pharma US | Myrbetriq | $147 | 5 payments
|
| Palette Life Sciences | None | $146 | 1 payment
|
| UroGen Pharma | Jelmyto | $99 | 4 payments
|
| Axonics | Axonics | $37 | 2 payments
|
| Urovant Sciences | Gemtesa | $22 | 1 payment
|
| Boston Scientific | Rezum Generator | $22 | 1 payment
|
| Abbvie | Lupron Depot | $21 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $19 | 1 payment
|
| Blue Earth Diagnostics | Axumin | $17 | 1 payment
|
| Endo Pharmaceuticals | Aveed | $16 | 1 payment
|
| Pfizer | Xtandi | $15 | 1 payment
|
| Caldera Medical | Desara | $15 | 1 payment
|
2021: $37
| Blue Earth Diagnostics | Axumin | $22 | 1 payment
|
| Boston Scientific | Rezum | $15 | 1 payment
|
2019: $947
| Boston Scientific | General Female Sui | $932 | 5 payments
|
| C. R. Bard Inc. & Subsidiaries | None | $15 | 1 payment
|
Checkups this office reported
17 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 95.1 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Asked about smokingPatients asked about tobacco, with help to quit if they smoke | 58%That's more than half. | 627 |
| Blood pressure under controlPeople with high blood pressure whose reading was in a healthy range | 64%That's more than half. | 231 |
| Bone-density scans that were not neededYounger women who got a bone scan without a medical reason | 5%That's few of the people this applied to. Better on this measure. | 66 |
| Breast cancer screeningEligible women who got a mammogram | 80%That's most of the people this applied to. | 235 |
| Cervical cancer screeningEligible women who got a Pap or HPV test | 53%That's more than half. | 249 |
| Checked for fall riskOlder patients screened for fall risk | 31%That's less than half. | 551 |
| Colon cancer screeningEligible adults who got a colon cancer test | 49%That's less than half. | 577 |
| Depression screeningPatients screened for depression, with a follow-up plan if needed | 23%That's few of the people this applied to. | 894 |
See the other 9 measures
| Diabetes eye examPeople with diabetes who got a retinal eye exam | 21%That's few of the people this applied to. | 66 |
| Diabetes poorly controlledPeople with diabetes whose blood sugar stayed very high | 39%That's less than half. Better on this measure. | 66 |
| HIV screeningEligible patients who were screened for HIV | 25%That's less than half. | 591 |
| Medications listed in the chartVisits where the current medication list was documented | 40%That's less than half. | 2,377 |
| Oncology: Medical and Radiation - Pain Intensity QuantifiedAs Medicare defines this measure | 4% | 25 |
| Patients can see their records onlinePatients who were given electronic access to their health information | 100%That's most of the people this applied to. | 425 |
| Prescriptions sent electronicallyPrescriptions sent to the pharmacy by computer instead of paper | 99%That's most of the people this applied to. | 518 |
| Statin prescribed when it protects the heartPeople at cardiovascular risk who were prescribed a statin | 83%That's most of the people this applied to. | 287 |
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 31%That's less than half. | 1,087 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- Checks the state prescription-drug database before prescribing
- Did a security review of patient data
- Exchanges records both ways with other health systems
- Improved the patient portal
- Lets patients read their visit notes
- Shows lab and imaging costs when ordering tests
- Uses standard treatment protocols
- Exempt from electronic case reporting
- Exempt from immunization registry reporting
Professional record
- NPI
- 1649613365
- Licence
- CA A156420California A156420: Current · expires 2028-04-30
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Urology (208800000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2013-04-11
- NPI last updated
- 2025-09-02
- NPI record certified
- 2025-09-02
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 3300 Webster St Ste 710, Oakland, CA, 94609